Additional results from the MoveDMD trial with edasalonexent: MRI-measured preservation of muscle and age-appropriate growth through more than 1 year of treatment

MRI is a way to assess the muscles of boys with Duchenne and measures inflammation and fat infiltration. Two different types of MRI were used in the MoveDMD trial, MRI T2 and MRS fat fraction. Edasalonexent statistically significantly improved the rate of change of MRI T2 compared with the off-treatment control period (p<0.05 for 12, 24, 36 and 48 weeks of treatment). Decrease in progression of MRI T2 is consistent with slowing of disease progression observed in functional assessments. MRS fat fraction also showed less of an increase in boys on edasalonexent than during the off-treatment control period. *Assessments of muscle function and MRI results all consistently showed less disease progression on edasalonexent compared to the off-treatment control period*. As a reminder, the assessments of muscle function were the North Star Ambulatory Assessment and timed function tests (4-stair climb, 10-meter walk/run and time to stand).

Height and weight growth through 60 weeks of edasalonexent treatment was *age-appropriate and on track with standard growth curves for unaffected boys in the same age range*. BMI trended towards a decrease. This profile is favorably differentiated from the typical profile associated with the corticosteroid standard of care in DMD, which includes weight gain and curtailed growth. To see complete results to date, visit [www.catabasis.com](http://www.catabasis.com).

**MRI T2: Composite of 5 Lower Leg Muscles**

![Graph showing annual rate of change in MRI T2 for control and edasalonexent treatment](image)

Means ± SEM shown; *p<0.05 for mixed model comparison with off-treatment period

Positive MoveDMD data support the planned Phase 3 trial for edasalonexent

We are preparing for a Phase 3 trial that will enroll approximately 125 boys with DMD between the ages of 4-7 years old regardless of mutation type and who have not been on steroids for at least 6 months. It is planned to be a single, global, placebo-controlled Phase 3 trial with 2 boys receiving edasalonexent for every 1 boy receiving placebo. After 12 months in the trial, all boys are expected to receive edasalonexent in an open-label extension.
The information provided here is for parents and caregivers of boys with Duchenne muscular dystrophy (DMD). Edasalonexent is an investigational drug that has not been approved by the US Food and Drug Administration.